HRTX
Heron Therapeutics Inc

7,338
Mkt Cap
$201.7M
Volume
1.1M
52W High
$2.68
52W Low
$1.05
PE Ratio
-13.60
HRTX Fundamentals
Price
$1.10
Prev Close
$1.11
Open
$1.11
50D MA
$1.23
Beta
1.43
Avg. Volume
1.55M
EPS (Annual)
-$0.0891
P/B
28.71
Rev/Employee
$1.18M
Loading...
Loading...
News
all
press releases
What is Northland Capmk's Estimate for HRTX FY2026 Earnings?
Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Equities research analysts at Northland Capmk issued their FY2026 earnings estimates for Heron Therapeutics in a research report issued to...
MarketBeat·8d ago
News Placeholder
More News
News Placeholder
What is HC Wainwright's Forecast for HRTX FY2025 Earnings?
Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Equities research analysts at HC Wainwright dropped their FY2025 earnings per share (EPS) estimates for Heron Therapeutics in a research note...
MarketBeat·9d ago
News Placeholder
What is HC Wainwright's Forecast for HRTX FY2027 Earnings?
Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Research analysts at HC Wainwright cut their FY2027 earnings per share (EPS) estimates for Heron Therapeutics in a report released on Tuesday...
MarketBeat·10d ago
News Placeholder
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·12d ago
News Placeholder
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -150.00% and -0.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
News Placeholder
Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·3mo ago
News Placeholder
Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -100.00% and -1.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Zacks·5mo ago
News Placeholder
Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025
Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025 Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On...
PR Newswire·9mo ago
News Placeholder
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina PR Newswire SAN DIEGO...
PR Newswire·11mo ago

Latest HRTX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.